

[Click here to access the guidelines/NICE algorithm](#)

N&WICS - TA599 - Sodium zirconium cyclosilicate - Hyperkalaemia

Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given: ☐

If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage and price per dose) unless an order of preference is stated in the TAs. ☐

Patient NHS No:	Trust:	Practice Name:
Patient Hospital No: <input type="text"/>	Consultant Making Request: <input type="text"/>	Practice Postcode:
Patient's Initials and DoB:		Practice Code:
Notification Email Address: <input type="text"/> (@NHS.net account ONLY)		Contact name & number: <input type="text"/>
Start date of requested treatment: <input type="text"/>	Provider: <input type="checkbox"/> Private <input type="checkbox"/> NHS Supplier: <input type="checkbox"/> Homecare <input type="checkbox"/> Hospital	Sub-Type: <input type="text"/> N/A <input type="button" value="v"/> (if applicable)

By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR).

For support regarding IFRs, please contact: norfolkicd@nhs.net

For support regarding the criteria listed below, please contact: norfolknontariff@nhs.net

Please indicate whether patient meets the following NICE criteria:		Please tick
1. Sodium zirconium cyclosilicate is recommended as an option for treating hyperkalaemia in adults only if used: <ul style="list-style-type: none">• in emergency care for acute life-threatening hyperkalaemia alongside standard care or• for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they:• have a confirmed serum potassium level of at least 6.0 mmol/litre and• because of hyperkalaemia, are not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor and• are not on dialysis. [amended 2022]		<input type="checkbox"/> Yes <input type="checkbox"/> No
2. Stop sodium zirconium cyclosilicate if RAAS inhibitors are no longer suitable. [amended 2022]		<input type="checkbox"/> Yes <input type="checkbox"/> No
I confirm that the patient meets the criteria for treatment		
Name of person completing: <input type="text"/>	Contact Details: <input type="text"/>	
Designation of person completing: <input type="text"/>	Date: <input type="text"/>	
Trust Authorising Pharmacist		
Name: <input type="text"/>		
Date: <input type="text"/>		

